{"id":380108,"date":"2020-11-12T14:15:36","date_gmt":"2020-11-12T19:15:36","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=380108"},"modified":"2020-11-12T14:15:36","modified_gmt":"2020-11-12T19:15:36","slug":"intercept-pharmaceuticals-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-that-a-securities-class-action-lawsuit-has-been-filed-on-behalf-of-shareholders-of-intercept","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/intercept-pharmaceuticals-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-that-a-securities-class-action-lawsuit-has-been-filed-on-behalf-of-shareholders-of-intercept\/","title":{"rendered":"INTERCEPT PHARMACEUTICALS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Securities Class Action Lawsuit has Been Filed on Behalf of Shareholders of Intercept Pharmaceuticals, Inc."},"content":{"rendered":"

\nImpending Lead Plaintiff Deadline is January 4, 2021
\n<\/h2>\n
\n

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP<\/a> (\u201cWolf Haldenstein\u201d) announces that a federal securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors who purchased or otherwise acquired Intercept Pharmaceuticals, Inc. (\u201cIntercept\u201d or the \u201cCompany\u201d) (NASDAQ:\u00a0ICPT) securities between\u00a0September 28, 2019 and October 7, 2020\u00a0inclusive (the \u201cClass Period\u201d).<\/p>\n

\n All <\/strong>
\n i<\/strong>
\n nvestors <\/strong>
\n who<\/strong>
\n purchased<\/strong>
\n shares<\/strong>
\n of<\/strong>
\n Intercept Pharmaceuticals, Inc.<\/strong>
\n a<\/strong>
\n nd<\/strong>
\n incurred losses <\/strong>
\n a<\/strong>
\n re<\/strong>
\n u<\/strong>
\n rged<\/strong>
\n to contact the firm <\/strong>
\n i<\/strong>
\n mmediately at <\/strong>
\n
\n classmember@whafh.com<\/strong>
\n <\/a>
\n or (800) 575-0735 or (212) 545-4774.<\/strong>
\n You may obtain additional information conc<\/strong>
\n erning the action or <\/strong>
\n
\n join the case<\/strong>
\n <\/a>
\n on our <\/strong>
\n website<\/strong>
\n , <\/strong>
\n
\n www.whafh.com.<\/strong>
\n <\/a>\n <\/p>\n

If you have incurred losses in the shares of Intercept Pharmaceuticals, Inc.,<\/strong>you<\/strong> may,<\/strong>no<\/strong>later than<\/strong> January 4, 2021,<\/strong>\u00a0\u00a0 request that the Court appoint you lead plaintiff of the proposed class.\u00a0\u00a0<\/p>\n

\n
\n CLICK HERE TO JOIN THIS CASE<\/strong>
\n <\/a>\n <\/p>\n

The filed complaint alleges that throughout the Class Period, Defendants made materially false and\/or misleading statements, as well as failed to disclose material adverse facts about the Company\u2019s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that:<\/p>\n